ReviewEndocrinology, diabetes & metabolism2025
Irisin, the Myokine: Guardian and Mediator in Cardiovascular System.
Review in Endocrinology, diabetes & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Cardiometabolic Aging Driven by Multi-Organ Crosstalk: Mechanisms and Therapeutic Strategies.International journal of molecular sciences · 2026Review
- MG53, a Regenerative Myokine Linking Skeletal Muscle to Cardiac Repair.Biomolecules · 2026Review
- Musculoskeletal Assessment in Patients with Adrenal Incidentalomas: Should We Integrate the Trabecular Bone Score and/or Circulating Irisin?Diagnostics (Basel, Switzerland) · 2026Article
- Exerkines in diabetic retinopathy: from mechanisms to therapeutic prospects.Frontiers in endocrinology · 2026Review
- Irisin, the Myokine: Guardian and Mediator in Cardiovascular System.Endocrinology, diabetes & metabolism · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular diseases pose a significant challenge to global health, and the role of exercise as a non-pharmacological intervention has attracted considerable attention. Irisin, a myokine released during exercise, exhibits excellent potential in regulating metabolism. Its potential intervention value in metabolic and neurodegenerative diseases has been preliminarily confirmed by correlational studies and animal experiments.
objectiveTo reveal the unique role of Irisin in the cardiovascular field and clarify its regulatory mechanisms and clinical application prospects in cardiovascular health.
methodsBy comprehensively reviewing existing studies, this paper systematically summarizes the therapeutic effects and molecular mechanisms of Irisin in various cardiovascular diseases (such as atherosclerosis, myocardial infarction, myocardial ischemia-reperfusion injury, and heart failure) and cerebrovascular diseases (including ischemic stroke, hemorrhagic stroke, and post-stroke depression), and further explores its association with perivascular adipose tissue. RESULTS/CONTENT: Irisin demonstrates multi-dimensional therapeutic potential in the aforementioned cardiovascular and cerebrovascular diseases. Its mechanisms of action involve multiple aspects such as metabolic regulation, inflammation inhibition, and tissue repair. Additionally, it has a close mutual regulatory relationship with perivascular adipose tissue, collectively forming a complex regulatory network for cardiovascular health.
conclusionThis review provides a theoretical basis for the clinical application of Irisin in cardiovascular diseases, not only opening up new research and application directions but also further highlighting the unique significance of exercise and Irisin in maintaining cardiovascular health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.